Fig. 4.

GV-971 modifies cytokine and chemokine levels in peripheral blood and cortical tissues. (a) Quantification of cytokine and chemokine concentrations in the serum of APPPS1-21 male mice treated with 160mg/kg GV-971 or vehicle from the University of Chicago (n = 10–11). (b) Quantification of cytokine and chemokine concentrations in the serum of APPPS1-21 female mice treated with 160mg/kg GV-971 or vehicle (n = 8–10). (c) Quantification of cytokine and chemokine concentrations in the serum of 5XFAD male mice treated with 100mg/kg GV-971 or vehicle from Washington University in St. Louis (n = 12–13). (d) Quantification of cytokine and chemokine concentrations in the serum of 5XFAD female mice treated with 100mg/kg GV-971 or vehicle (n = 9–12). (e) Quantification of cytokine and chemokine concentrations in the cortical tissue of 5XFAD male mice treated with 100mg/kg GV-971 or vehicle (n = 12–13). Data presented as SEM. Significance determined using unpaired t-test. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001